Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Background: CT-P13 is a biosimilar of Remicade, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD.

Aims: To assess the effectiveness and safety of CT-P13 in IBD patients in real clinical practice.